Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRestructuring CostsRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Ratios

Icu Medical (ICUI) Shares Outstanding (Diluted Average) (2016 - 2025)

Icu Medical's Shares Outstanding (Diluted Average) history spans 17 years, with the latest figure at $24.9 million for Q4 2025.

  • For the quarter ending Q4 2025, Shares Outstanding (Diluted Average) rose 2.12% year-over-year to $24.9 million, compared with a TTM value of $24.9 million through Dec 2025, up 2.12%, and an annual FY2025 reading of $24.9 million, up 2.12% over the prior year.
  • Shares Outstanding (Diluted Average) for Q4 2025 was $24.9 million at Icu Medical, up from $24.7 million in the prior quarter.
  • The five-year high for Shares Outstanding (Diluted Average) was $24.9 million in Q4 2025, with the low at $21.7 million in Q1 2021.
  • Average Shares Outstanding (Diluted Average) over 5 years is $23.7 million, with a median of $24.1 million recorded in 2023.
  • Year-over-year, Shares Outstanding (Diluted Average) increased 10.11% in 2022 and then fell 0.06% in 2024.
  • Tracing ICUI's Shares Outstanding (Diluted Average) over 5 years: stood at $21.8 million in 2021, then rose by 9.58% to $23.9 million in 2022, then rose by 0.93% to $24.1 million in 2023, then increased by 1.23% to $24.4 million in 2024, then increased by 2.12% to $24.9 million in 2025.
  • Per Business Quant, the three most recent readings for ICUI's Shares Outstanding (Diluted Average) are $24.9 million (Q4 2025), $24.7 million (Q3 2025), and $24.7 million (Q2 2025).